Shilpa Medicare Q4FY21 consolidated PAT at Rs. 7.82 Cr

The company has posted net profit of Rs.147.78 crores for the 12 months period ended March 31, 2021

Shilpa Medicare Jadcherla facility gets GMP certification from Russia

The GMP certificate is valid for three years until April 2024.

Shilpa Medicare to produce 50 mn doses of Sputnik V Vaccine

Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production

Shilpa Medicare CFO resigns

The commercial production in the SML was started in November 1989.

Shilpa Pharma Lifesciences’ Unit II, Raichur, Karnataka clears PMDA Japan, GMP inspection

The inspection has concluded successfully on 1st September 2023 without any critical/major observation

ShilpaMedicare Q1FY23 consolidated PAT drops to to Rs. 84.85 lakhs

Mylab partners with Shilpa Biologicals for vaccines and therapeutics segment

Shilpa Biologicals has tie-ups with Zydus to supply ZyCoV-D vaccine drug substance and Dr Reddy’s to make Sputnik V from its facility in Dharwad

Zydus supplies first consignment of its Covid-19 vaccine ZyCoV-D

The vaccine will be priced at Rs. 265 per dose and the applicator being offered at Rs. 93 per dose excluding GST

Shilpa Biologics permitted to conduct Phase 1 study on NavAlbumin

The product is synthetically developed as compared to the current process of drawing the same from blood plasma and is backed by a granted global patent